// +author:e anttila +author:anttila 
var _ajax_res = {
  hits: 15,

  first: 0,

  results: [

{userid:"marc.arbyn", "refid":"76","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination","year":"2009","author":"E Lynge, A Anttila, M Arbyn, N Segnan, G Ronco","journal":"Eur J Cancer","volume":"45","number":"15","pages":"2714-21","month":"October","doi":"doi:10.1016\/j.ejca.2009.07.024 ","pubmed":"19695870","pdflink":"","urllink":"","abstract":"","note":"","tags":""}
,

{userid:"marc.arbyn", "refid":"77","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Trends of cervical cancer mortality in the member states of the European Union","year":"2009","author":"M Arbyn, AO Raifu, F Bray, E Weiderpass A Anttila","journal":"Eur J Cancer","volume":"45","number":"15","pages":"2640-8","month":"October","doi":"doi:10.1016\/j.ejca.2009.07.018   ","pubmed":"19695864","pdflink":"","urllink":"","abstract":"Background Cervical cancer mortality can be avoided to a large extent by screening and treatment of screen-detected cervical lesions. However, in 2004, more than 16,000 women died from cervical cancer in the European Union (EU). In the current paper, we analyse cervical cancer mortality trends in the 27 member states since 1970 and, subsequently, try to explain how screening and other factors have driven changes.Methods Data on number of deaths from uterine cancers and overall female populations from EU member states were extracted from the World Health Organisation mortality database. Three different reallocation rules were applied to correct cervical cancer mortality for inaccuracies in certification of cause of death of not otherwise specified uterine cancer. Joinpoint regression was used to study annual variation of corrected cervical cancer mortality in all member states. We distinguished the 15 old from the 12 new member states, which acceded to the EU in 2004 or later. For Finland, France and Romania, age-specific trends by calendar period and the standardised cohort mortality ratios by birth cohort were analysed.Results Corrected age-standardised cervical cancer mortality rates have decreased significantly over the past decades in the old member states. Member states in Eastern Europe and also the Baltic states showed mortality rates that decreased at a lower intensity (Czech Republic, Poland), remained constant at a high rate (Estonia, Slovakia) or even increased (Bulgaria, Latvia, Lithuania, Romania). The standardised cohort mortality ratio indicated that mortality does not decrease further or even increase among women born after 1940.Conclusion Remarkable contrasts were observed on cervical cancer mortality, in particular, between the old and new member states of the EU, which might probably be explained by differences in preventive strategies. This contrast might increase in the future, unless adequate preventive measures are adopted","note":"","tags":"cervical cancer, mortality, trend analysis, Europe"}
,

{userid:"marc.arbyn", "articletype":"article","pages":"935-941","author":"A Anttila, G Ronco, G Clifford, F Bray, M Hakama, M Arbyn, E Weiderpass","year":"2004","title":"Cervical cancer screening programmes and policies in 18 European countries.","month":"Aug","journal":"Br J Cancer","publisher":"","volume":"91","number":"5","note":"","tags":"Adolescent,Adult,Aged,Europe,Female,Humans,International Cooperation,Mass Screening,Middle Aged,Public Policy,Questionnaires,Uterine Cervical Neoplasms","booktitle":"","editor":"","abstract":"A questionnaire survey was conducted by the Epidemiology Working Group of the European Cervical Cancer Screening Network, and the International Agency for Research on Cancer, IARC, between August and December 2003 in 35 centres in 20 European countries with reliable cervical cancer incidence and\/or mortality data in databanks held at IARC and WHO. The questionnaire was completed by 28 centres from 20 countries. The final tables included information on 25 centres from 18 countries. Six countries had started screening in the 1960s, whereas 10 countries or regions had started at least a pilot programme by 2003. There were six invitational and nine partially invitational programmes, the rest employing opportunistic screening only. Recommended lifetime number of smears varied from seven to more than 50. Coverage of smear test within the recommended screening interval (usually 3 or 5 years) was above 80% in three countries. Screening registration took place in 13 programmes. Eight programmes reported the rates of screen-detected cervical cancers and precursor lesions. There was wide variation in the CIN3 detection rates. International guidelines and quality assurance protocols are useful for monitoring and evaluating screening programmes systematically. Our survey indicated that the recommendations as currently given are met in only few European countries. Health authorities need to consider stronger measures and incentives than those laid out in the current set of recommendations.","address":"","school":"","issn":"0007-0920","doi":"10.1038\/sj.bjc.6602069","pubmed":"15280916","key":"Anttila2004","howpublished":"","urllink":"","refid":30}
,

{userid:"tobias.kurth", "articletype":"article","pages":"e1004366","author":"Daniel I Chasman, Verneri Anttila, Julie E Buring, Paul M Ridker, Markus Sch\u00fcrks, Tobias Kurth,  ","year":"2014","title":"Selectivity in genetic association with sub-classified migraine in women.","month":"May","journal":"PLoS genetics","publisher":"","volume":"10","number":"5","note":"","tags":"original paper,Case-Control Studies,Female,Humans,Middle Aged,Migraine Disorders,Polymorphism, Single Nucleotide","booktitle":"","editor":"","abstract":"Migraine can be sub-classified not only according to presence of migraine aura (MA) or absence of migraine aura (MO), but also by additional features accompanying migraine attacks, e.g. photophobia, phonophobia, nausea, etc. all of which are formally recognized by the International Classification of Headache Disorders. It remains unclear how aura status and the other migraine features may be related to underlying migraine pathophysiology. Recent genome-wide association studies (GWAS) have identified 12 independent loci at which single nucleotide polymorphisms (SNPs) are associated with migraine. Using a likelihood framework, we explored the selective association of these SNPs with migraine, sub-classified according to aura status and the other features in a large population-based cohort of women including 3,003 active migraineurs and 18,108 free of migraine. Five loci met stringent significance for association with migraine, among which four were selective for sub-classified migraine, including rs11172113 (LRP1) for MO. The number of loci associated with migraine increased to 11 at suggestive significance thresholds, including five additional selective associations for MO but none for MA. No two SNPs showed similar patterns of selective association with migraine characteristics. At one extreme, SNPs rs6790925 (near TGFBR2) and rs2274316 (MEF2D) were not associated with migraine overall, MA, or MO but were selective for migraine sub-classified by the presence of one or more of the additional migraine features. In contrast, SNP rs7577262 (TRPM8) was associated with migraine overall and showed little or no selectivity for any of the migraine characteristics. The results emphasize the multivalent nature of migraine pathophysiology and suggest that a complete understanding of the genetic influence on migraine may benefit from analyses that stratify migraine according to both aura status and the additional diagnostic features used for clinical characterization of migraine.","address":"","school":"","issn":"1553-7404","doi":"10.1371\/journal.pgen.1004366","isi":"","pubmed":"24852292","key":"Chasman2014","howpublished":"","urllink":"http:\/\/www.plosgenetics.org\/article\/info:doi\/10.1371\/journal.pgen.1004366","refid":308,"weight":308,"pdflink":"http:\/\/www.plosgenetics.org\/article\/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pgen.1004366&representation=PDF"}
,

{userid:"marc.arbyn", "refid":"198","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"European Guidelines for Quality Assurance in Cervical Cancer Screening: Supplements to the 2nd Edition","year":"2015","author":"von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, Tornberg S, Anttila A","journal":"Human Papillomavirus Research","volume":"1","number":"1","pages":"22-31","month":"","doi":"doi:10.1016\/j.pvr.2015.06.006","pubmed":"","pdflink":"","urllink":"","abstract":"In a project coordinated by the International Agency for Research on Cancer (IARC) 31 experts from 11 European countries and IARC have developed supplements to the current European guidelines for quality assurance in cervical cancer screening. The supplements take into account the potential of primary testing for human papillomavirus (HPV) and vaccination against HPV infection to improve cervical cancer prevention and control and will be published by the European Commission in book format. They include 62 recommendations or conclusions for which the strength of the evidence and the respective recommendations is graded. While acknowledging the available evidence for more efficacious screening using HPV primary testing compared to screening based on cytology, the authors and editors of the supplements emphasize that appropriate policy and programme organization remain essential to achieve an acceptable balance between benefit and harm of any screening or vaccination programme. A summary of the supplements and all of the graded recommendations are presented here in journal format to make key aspects of the updated and expanded guidelines known to a wider professional and scientific community.","note":"","tags":"","weight":198}
,

{userid:"marc.arbyn", "refid":"44","attachment":"","articletype":"article","sectionheading":"","title":"Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectiveness.","year":"2000","author":"M van Ballegooijen, E van den Akker-van Marle, J Patnick, E Lynge, M Arbyn, A Anttila, G Ronco, J Dik, F Habbema","journal":"Eur J Cancer","volume":"36","number":"17","pages":"2177-2188","month":"Nov","doi":"10.1016\/S0959-8049(00)00330-0","pubmed":"11072201","pdflink":"","urllink":"","abstract":"The objective was the evaluation of the (cost-)effectiveness of cervical cancer screening in the European Union (EU) countries. Data were collected on recommended screening age ranges and intervals, coverage, proportion of non-negative smears and smear use. Estimates reported by representatives of each participating Member State were compared, and used as input for model based on (using the MISCAN simulation model for cancer screening) effectiveness and cost-effectiveness calculations. Differences in coverage from below 50 to 82% resulted in more or less proportional differences in expected percentage life-years lost reduction, almost regardless of differences in 7-50+ smears recommended in a lifetime. Differences in screening intensity (resulting from the recommended number of smears per lifetime and the number of excess smears on top of these recommendations) resulted in more than 2-fold difference in the expected number of smears per percentage life-years lost reduction. (Cost-)effectiveness predictions would have greatly improved if estimates of long-term coverage had also been available. To conclude, estimates for a restricted set of well defined parameters - a few for short and long-term coverage and one for the total number of smears - are quite useful for country-specific (cost-)effectiveness evaluations. The main, and to some extent, unsolvable problem for further improvement of the analysis is the lack of reliable country-specific estimates for the background risk of cervical cancer in women eligible for screening in the near future.","note":"","tags":"Age Distribution,Cost-Benefit Analysis,Europe,European Union,Female,Humans,Mass Screening,Quality-Adjusted Life Years,Sensitivity and Specificity,Uterine Cervical Neoplasms,Vaginal Smears"}
,

{userid:"faustobiancari", "articletype":"article","pages":"483-487","author":"Anna Lautam\u00e4ki, K E Juhani Airaksinen, Tuomas Kiviniemi, Giulia Vinco, Flavio Ribichini, Jarmo Gunn, Vesa Anttila, Jouni Heikkinen, Kari Korpilahti, Pasi Karjalainen, Olli Kajander, Markku Eskola, Erkki Ilveskoski, Tomas Axelsson, Tomas Gudbjartsson, Anders Jeppsson, Fausto Biancari","year":"2014","title":"Prognosis and disease progression in patients under 50 years old undergoing PCI: the CRAGS (Coronary aRtery diseAse in younG adultS) study.","month":"Aug","journal":"Atherosclerosis","publisher":"","volume":"235","number":"2","note":"","tags":"","booktitle":"","editor":"","abstract":"Young patients undergoing percutaneous coronary intervention (PCI) are generally considered at low procedural risk, but the potentially aggressive nature of coronary artery disease and long expectancy of life expose them to a high risk of recurrent coronary events. The extent and determinants of disease progression in this patient subset remain largely unknown. The aim of the present study was to evaluate general risk factors for late outcomes among patients \u226450 years old who underwent PCI.","address":"","school":"","issn":"1879-1484","doi":"10.1016\/j.atherosclerosis.2014.05.953","isi":"","pubmed":"24953487","key":"Lautam\u00e4ki2014","howpublished":"","urllink":"","refid":177,"weight":177}
,

{userid:"tfreilinger", "refid":"36","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Genome-wide association study reveals three susceptibility loci for common migraine in the general population.","year":"2011","author":"Daniel I Chasman, Markus Sch\u00fcrks, Verneri Anttila, Boukje de Vries, Ulf Schminke, Lenore J Launer, Gisela M Terwindt, Arn M J M van den Maagdenberg, Konstanze Fendrich, Henry V\u00f6lzke, Florian Ernst, Lyn R Griffiths, Julie E Buring, Mikko Kallela, Tobias Freilinger, Christian Kubisch, Paul M Ridker, Aarno Palotie, Michel D Ferrari, Wolfgang Hoffmann, Robert Y L Zee, Tobias Kurth","journal":"Nat Genet","volume":"43","number":"","pages":"695-698","month":"","doi":"10.1038\/ng.856","pubmed":"21666692","pdflink":"","urllink":"","abstract":"Migraine is a common, heterogeneous and heritable neurological disorder. Its pathophysiology is incompletely understood, and its genetic influences at the population level are unknown. In a population-based genome-wide analysis including 5,122 migraineurs and 18,108 non-migraineurs, rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113 (12q13.3, LRP1) were among the top seven associations (P < 5 \u00d7 10(-6)) with migraine. These SNPs were significant in a meta-analysis among three replication cohorts and met genome-wide significance in a meta-analysis combining the discovery and replication cohorts (rs2651899, odds ratio (OR) = 1.11, P = 3.8 \u00d7 10(-9); rs10166942, OR = 0.85, P = 5.5 \u00d7 10(-12); and rs11172113, OR = 0.90, P = 4.3 \u00d7 10(-9)). The associations at rs2651899 and rs10166942 were specific for migraine compared with non-migraine headache. None of the three SNP associations was preferential for migraine with aura or without aura, nor were any associations specific for migraine features. TRPM8 has been the focus of neuropathic pain models, whereas LRP1 modulates neuronal glutamate signaling, plausibly linking both genes to migraine pathophysiology.","note":"","tags":"Case-Control Studies,Chromosomes, Human, Pair 1,Chromosomes, Human, Pair 12,Chromosomes, Human, Pair 2,Cohort Studies,Female,Genetic Loci,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Male,Middle Aged,Migraine without Aura,Polymorphism, Single Nucleotide,Prognosis,Risk Factors,United States","publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"1546-1718","isi":"","key":"Chasman2011","howpublished":""}
,

{userid:"tobias.kurth", "refid":"24","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Genome-wide association study reveals three susceptibility loci for common migraine in the general population.","year":"2011","author":"Daniel I Chasman, Markus Sch\u00fcrks, Verneri Anttila, Boukje de Vries, Ulf Schminke, Lenore J Launer, Gisela M Terwindt, Arn M J M van den Maagdenberg, Konstanze Fendrich, Henry V\u00f6lzke, Florian Ernst, Lyn R Griffiths, Julie E Buring, Mikko Kallela, Tobias Freilinger, Christian Kubisch, Paul M Ridker, Aarno Palotie, Michel D Ferrari, Wolfgang Hoffmann, Robert Y L Zee, Tobias Kurth","journal":"Nat Genet","volume":"43","number":"7","pages":"695-698","month":"Jul","doi":"10.1038\/ng.856","pubmed":"21666692","pdflink":"","urllink":"","abstract":"Migraine is a common, heterogeneous and heritable neurological disorder. Its pathophysiology is incompletely understood, and its genetic influences at the population level are unknown. In a population-based genome-wide analysis including 5,122 migraineurs and 18,108 non-migraineurs, rs2651899 (1p36.32, PRDM16), rs10166942 (2q37.1, TRPM8) and rs11172113 (12q13.3, LRP1) were among the top seven associations (P < 5 \u00d7 10(-6)) with migraine. These SNPs were significant in a meta-analysis among three replication cohorts and met genome-wide significance in a meta-analysis combining the discovery and replication cohorts (rs2651899, odds ratio (OR) = 1.11, P = 3.8 \u00d7 10(-9); rs10166942, OR = 0.85, P = 5.5 \u00d7 10(-12); and rs11172113, OR = 0.90, P = 4.3 \u00d7 10(-9)). The associations at rs2651899 and rs10166942 were specific for migraine compared with non-migraine headache. None of the three SNP associations was preferential for migraine with aura or without aura, nor were any associations specific for migraine features. TRPM8 has been the focus of neuropathic pain models, whereas LRP1 modulates neuronal glutamate signaling, plausibly linking both genes to migraine pathophysiology.","note":"PMCID: PMC3125402 ","tags":"Original Paper,Case-Control Studies,Chromosomes, Human, Pair 1,Chromosomes, Human, Pair 12,Chromosomes, Human, Pair 2,Cohort Studies,Female,Genetic Loci,Genetic Predisposition to Disease,Genome-Wide Association Study,Humans,Male,Middle Aged,Migraine without Aura,Polymorphism, Single Nucleotide,Prognosis,Risk Factors,United States, Top 10, High Impact","publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"1546-1718","isi":"","key":"Chasman2011","howpublished":""}
,

{userid:"vincenza.colonna", "articletype":"article","pages":"519-523","author":"Aaron R Everitt, Simon Clare, Thomas Pertel, Sinu P John, Rachael S Wash, Sarah E Smith, Christopher R Chin, Eric M Feeley, Jennifer S Sims, David J Adams, Helen M Wise, Leanne Kane, David Goulding, Paul Digard, Verneri Anttila, J Kenneth Baillie, Tim S Walsh, David A Hume, Aarno Palotie, Yali Xue, Vincenza Colonna, Chris Tyler-Smith, Jake Dunning, Stephen B Gordon, Rosalind L Smyth, Peter J Openshaw, Gordon Dougan, Abraham L Brass, Paul Kellam","year":"2012","title":"IFITM3 restricts the morbidity and mortality associated with influenza.","month":"Apr","journal":"Nature","publisher":"","volume":"484","number":"7395","note":"","tags":"Alleles,Amino Acid Sequence,Animals,Cytokines,England,Gene Deletion,Humans,Influenza A Virus, H1N1 Subtype,Influenza A Virus, H3N2 Subtype,Influenza A virus,Influenza B virus,Influenza, Human,Leukocytes,Lung,Membrane Proteins,Mice,Mice, Inbred C57BL,Mice, Knockout,Molecular Sequence Data,Orthomyxoviridae Infections,Pneumonia, Viral,Polymorphism, Single Nucleotide,RNA-Binding Proteins,Scotland,Virus Replication","booktitle":"","editor":"","abstract":"The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferon-inducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses. Both the magnitude and breadth of the IFITM proteins' in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses. Using a knockout mouse model, we now test this hypothesis directly and find that IFITM3 is essential for defending the host against influenza A virus in vivo. Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-pathogenicity influenza virus, mirroring the destruction inflicted by the highly pathogenic 1918 'Spanish' influenza. Similar increased viral replication is seen in vitro, with protection rescued by the re-introduction of Ifitm3. To test the role of IFITM3 in human influenza virus infection, we assessed the IFITM3 alleles of individuals hospitalized with seasonal or pandemic influenza H1N1\/09 viruses. We find that a statistically significant number of hospitalized subjects show enrichment for a minor IFITM3 allele (SNP rs12252-C) that alters a splice acceptor site, and functional assays show the minor CC genotype IFITM3 has reduced influenza virus restriction in vitro. Together these data reveal that the action of a single intrinsic immune effector, IFITM3, profoundly alters the course of influenza virus infection in mouse and humans.","address":"","school":"","issn":"1476-4687","doi":"10.1038\/nature10921","isi":"","pubmed":"22446628","key":"Everitt2012","howpublished":"","urllink":"","refid":3}
  ]
}

;
ajaxResultsLoaded(_ajax_res);